Integra LifeSciences (NASDAQ:IART) Coverage Initiated by Analysts at Morgan Stanley

Investment analysts at Morgan Stanley initiated coverage on shares of Integra LifeSciences (NASDAQ:IARTGet Free Report) in a report issued on Monday,Briefing.com Automated Import reports. The brokerage set an “underweight” rating and a $20.00 price target on the life sciences company’s stock. Morgan Stanley’s target price suggests a potential downside of 18.63% from the company’s current price.

Other analysts have also recently issued research reports about the company. Citigroup increased their price objective on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a report on Tuesday, November 5th. BTIG Research upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th. Bank of America decreased their target price on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating on the stock in a report on Monday, October 7th. Finally, Truist Financial cut their price target on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a report on Monday, October 14th. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $23.00.

View Our Latest Stock Analysis on Integra LifeSciences

Integra LifeSciences Price Performance

NASDAQ IART opened at $24.58 on Monday. The company has a market cap of $1.90 billion, a PE ratio of -273.11, a price-to-earnings-growth ratio of 0.84 and a beta of 1.08. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. The firm’s 50-day simple moving average is $20.77 and its two-hundred day simple moving average is $23.98. Integra LifeSciences has a 52 week low of $16.81 and a 52 week high of $45.42.

Integra LifeSciences (NASDAQ:IARTGet Free Report) last released its quarterly earnings data on Monday, November 4th. The life sciences company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.39 by $0.02. The company had revenue of $380.80 million during the quarter, compared to the consensus estimate of $375.81 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. Integra LifeSciences’s revenue for the quarter was down .4% on a year-over-year basis. During the same period last year, the firm earned $0.76 EPS. Research analysts predict that Integra LifeSciences will post 2.45 earnings per share for the current year.

Hedge Funds Weigh In On Integra LifeSciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD lifted its holdings in shares of Integra LifeSciences by 6.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 35,421 shares of the life sciences company’s stock worth $1,256,000 after acquiring an additional 2,114 shares during the last quarter. Jane Street Group LLC boosted its holdings in shares of Integra LifeSciences by 181.1% in the 1st quarter. Jane Street Group LLC now owns 124,887 shares of the life sciences company’s stock worth $4,427,000 after purchasing an additional 80,463 shares in the last quarter. CWM LLC increased its position in shares of Integra LifeSciences by 50.8% during the 2nd quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock valued at $37,000 after purchasing an additional 425 shares during the last quarter. Olstein Capital Management L.P. raised its holdings in shares of Integra LifeSciences by 13.0% during the 2nd quarter. Olstein Capital Management L.P. now owns 113,000 shares of the life sciences company’s stock valued at $3,293,000 after buying an additional 13,000 shares in the last quarter. Finally, Cardinal Capital Management lifted its position in Integra LifeSciences by 9.5% in the 2nd quarter. Cardinal Capital Management now owns 34,034 shares of the life sciences company’s stock worth $992,000 after buying an additional 2,965 shares during the last quarter. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

(Get Free Report)

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.

Featured Stories

Analyst Recommendations for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.